Drug Trial Radar · NCT06144749
A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Feb 15, 2025
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Hillhurst Biopharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Nov 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.
Conditions
- Anemia, Sickle Cell
Interventions
HBI-002Drug
Oral liquid carbon monoxide drug product.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of Treatment Emergent Adverse Events, including adverse events of special interestTime frame: Day 1 to 44
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Cevaxin - The Panama Clinic
Panama City, Panama
Hospital Pacífica Salud
Panama City, Panama
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.